German biotech company MorphoSys has expanded its senior clinical development team with three new management appointments.
Regulatory affairs head Dr Gabriele Elbl (pictured right) joins MorphoSys from Munich-based biopharmaceutical company Wilex AG, where she was senior vice president of regulatory affairs.
Prior to that she worked as a scientific administrator at the EMA, London, and served as head of pharmaceutical department at Sanofi Winthrop in Munich.
Dr Ludger Langer moves to MorphoSys from contract research organisation PRA International to take up the position of head of clinical operations and project management.
He brings almost 20 years of clinical operations and project management experience to MorphoSys prior to which he was vice president, clinical operations, Europe, Asia-Pacific and Africa at PRA.
Finally MorphoSys has also appointed Dr Steffen Heeger as head of clinical research. He was previously head of medical affairs at Merck Serono, where he also led the global clinical development team for its cancer drug Erbitux.